Jing Christine Ye, MD, MSc
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1996 | Shanghai Jiao Tong University, Shanghai, CN, MSc |
| 1993 | Shanghai Jiao Tong University, Shanghai, CN, MD |
Postgraduate Training
| 2012-2015 | Clinical Fellowship, Hematology Oncology, Wayne State University, School of Medicine, Detroit, Michigan |
| 2009-2012 | Clinical Residency, Internal Medicine, Wayne State University, School of Medicine, Detroit, Michigan |
| 1996-1997 | Research Fellowship, The Hospital for Sick Children, Toronto |
Licenses & Certifications
| 2025 | State of Texas |
| 2016 | American Board of Internal Medicine- Hematology |
| 2015 | American Board of Internal Medicine- Oncology |
| 2012 | American Board of Internal Medicine |
| 2012 | State of Michigan |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor, MI, 2021 - 2023
Assistant Professor, Department of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor, MI, 2015 - 2021
Administrative Appointments/Responsibilities
Vice-Chair, NCI SWOG Multiple Myeloma Committee, 2022 - Present
Co-Chair, Big Ten Cancer Research Consortium (BTCRC), 2022 - 2023
Other Professional Positions
Research Associate, Wayne State University, Detroit, MI, 2003 - 2009
Chief Operating Officer, SeeDNA Biotech, Toronto/Windsor, 1997 - 2009
Extramural Institutional Committee Activities
Panelist, NCCN (National Comprehensive Cancer Network), National Comprehensive Cancer Network, 2025 - Present
Member, Faculty Senate Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Credentialing Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, SRC Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Pharmacy & Therapeutic Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-Chair, Great Lakes Amyloidosis and Multiple Myeloma (GLAMM) Joint Journal Club (CME activity), University of Michigan, Rogel Cancer Center, 2021 - 2023
Editorial Activities
Associate editor, Frontiers, 2022 - Present
Editorial Board Member, Molecular Cytogenetics (the official journal of the European Cytogeneticists Association), 2020 - Present
Honors & Awards
| 2019 | SWOG Young Investigator Training Award |
| 2017 - 2018 | Clinical Trial Academy |
| 2012 | HONORS Research Award |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2021. A New Era in Multiple Myeloma Treatment. Conference. A New Era in Multiple Myeloma Treatment. Newport News, VA, US.
- 2020. Panelist for Multiple Myeloma Management Case Discussions. Conference. Panelist for Multiple Myeloma Management Case Discussions, FL, US.
National Presentations
- 2025. OncLive. Peer Exchange. Chicago, IL, US.
- 2025. CAHON Post-ASH Updates, US.
- 2022. Multiple Myeloma Updates. Conference. Multiple Myeloma Updates. Chicago, IL, US.
- 2022. Minimal Residual Disease in Multiple Myeloma. Conference. Minimal Residual Disease in Multiple Myeloma, US.
- 2022. 2022 Hematology Highlights: A Post ASH Review. A New Era of Immunotherapy in Multiple Myeloma. Conference. 2022 Hematology Highlights: A Post ASH Review. A New Era of Immunotherapy in Multiple Myeloma. Omaha, NE, US.
- 2021. New Paradigm of Frontline Treatment in Newly Diagnosed Multiple Myeloma. Conference. New Paradigm of Frontline Treatment in Newly Diagnosed Multiple Myeloma, US.
- 2020. Post-ASH Winter Symposium: Advances in Multiple Myeloma. Conference. Post-ASH Winter Symposium: Advances in Multiple Myeloma, US.
- 2019. 2019 Updates for Multiple Myeloma Management. Conference. 2019 Updates for Multiple Myeloma Management, FL, US.
- 2019. How to Establish a Clinical Research Portfolio. Conference. How to Establish a Clinical Research Portfolio. New York, NY, US.
- 2019. How to Manage Newly Diagnosed Multiple Myeloma?. Conference. How to Manage Newly Diagnosed Multiple Myeloma?. Detroit, MI, US.
International Presentations
- 2025. Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma. Panelist. Paris, FR.
- 2025. Chromoanagenesis, a subtype of genome chaos, in multiple myeloma: integrating clinical data with optical genomic mapping, FR.
- 2024. Minimal Residual Disease (MRD) guided myeloma treatment. Bermuda, US.
Formal Peers
- 2020. Decipher Genes, Chromosomes and Novel Therapeutic Strategies in Multiple Myeloma. Invited, US.
- 2018. Step Into Immuno-Oncology in Multiple Myeloma. Invited, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Immune Atlas Program: Gene Expression Profiling of the Bone Marrow Microenvironment in Multiple Myeloma |
| Funding Source: | MMRF |
| Role: | PI |
| Date: | 2017 - 2021 |
| Title: | Participation Agreement for PINR (MMRC-060): Phase II trial of IXAZOMIB and Dexamethasone versus IXAZOMIB, Dexamethasone and Lenalidomide, Randomized with NFKB2 rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) |
| Funding Source: | Millennium Pharmaceuticals |
| Role: | PI |
| Date: | 2017 - 2020 |
| Title: | Clinical Trial Agreement for Protocol 13-601: A phase 1/2a open-label, multi-dose, multi-center escalation and exploratory study of cerdulatinib (prt062070) in patients with relapsed/refractory chronic lymphocytic leukemia (cll)/ small lymphocytic lymphoma (sll) or b-cell or t-cell non-hodgkin lymphoma (nhl) |
| Funding Source: | Portola Pharmaceuticals |
| Role: | PI |
| Title: | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| Funding Source: | Regeneron |
| Role: | PI |
| Title: | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome |
| Funding Source: | Genmab |
| Role: | PI |
| Title: | A Phase Ib/II Open-Label Study of APG2575 in Combination with Novel Therapeutic Regimens in Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin Light Chain Amyloidosis Ascentage- 22-PAF02911 |
| Funding Source: | Multiple Myeloma Research Foundation |
| Role: | PI |
| Title: | Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma |
| Funding Source: | Janssen Research and Development |
| Role: | PI |
| Title: | A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma |
| Funding Source: | Janssen Research and Development |
| Role: | PI |
| Title: | Phase 1/2 FIH Study Of Regn5459 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) In Patients With Relapsed Or Refractory Multiple Myeloma |
| Funding Source: | Regeneron Pharmaceuticals |
| Role: | Co-I |
| Title: | A Phase I Dose-Escalation Study of the Selective PKC-ß Inhibitor MS- 553 In Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Funding Source: | Mingsight Pharmaceuticals, Inc |
| Role: | PI |
| Title: | Clinical-Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies |
| Funding Source: | Multiple Myeloma Research Foundation |
| Role: | PI |
| Title: | A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma |
| Funding Source: | GSK |
| Role: | PI |
| Title: | Phase III Study of Daratumumab/rhuPH20 (NSC-810307) + Lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy inpatients with multiple myeloma using minimal residual disease to direct therapy duration (drammatic M-Cube Grant: Functional and clinically relevant T/NK cell subset screening from deep immune profiling in multiple myeloma using CYTOF |
| Funding Source: | MCube |
| Role: | PI |
| Title: | Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen |
| Funding Source: | Multiple Myeloma Research Foundation |
| Role: | PI |
| Title: | Phase 2 Study with Minimal Residual Disease (MRD) driven adaptive strategy in treatment for newly diagnosed multiple myeloma with upfront daratumumab-based therapy |
| Funding Source: | Janssen Scientific Affairs |
| Role: | PI |
| Title: | A Phase 1, Open-Label, Multi-Center, Dose Escalation And Dose Expansion Study Of Nktr-255 As A Single Agent In Relapsed Or Refractory Hematological Malignancies And In Combination With Daratumumab As A Salvage Regimen For Multiple Myeloma |
| Funding Source: | Nektar Therapeutics |
| Role: | PI |
| Title: | A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12) |
| Funding Source: | GlaxoSmithKline LLC |
| Role: | PI |
| Title: | Decipher Immune Signatures and Therapeutic Response in Multiple Myeloma Patients |
| Funding Source: | The Joint Institute for Translational and Clinical Research |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Shaji K Kumar MD, Natalie S Callander MD, Kehinde Adekola MD, Larry D Anderson Jr MD, Muhamed Baljevic MD, Rachid Baz MD, Campagnaro E, Caitlin Costello MD, Christopher D’Angelo MD, Benjamin Derman MD, Srinivas Devarakonda MD, Noura Elsedawy MD, Amandeep Godara MD, Kelly Godby MD, Jens Hillengass MD, Leona Holmberg MD, Myo Htut MD, Carol Ann Huff MD, Malin Hultcrantz MD, Yubin Kang MD, Sarah Larson MD, Hans C Lee MD, Michaela Liedtke MD, Thomas Martin MD, James Omel MD, Timothy J Robinson MD, Aaron Rosenberg MD, Shayna R Sarosiek MD, Mark A Schroeder MD, Daniel Sherbenou MD, Suvannasankha A, Jason Valent MD, Asya Nina Varshavsky-Yanovsky MD, Dan Vogl MD, Jing Christine Ye MD, Kovach E, Kumar PhD AR. Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw 24(1):e260001, 2026. e-Pub 2026.
- Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodriguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosinol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. N Engl J Med, 2025. e-Pub 2025. PMID: 41358582.
- Voorhees PM, Kumar S, Usmani SZ, Ye JC, Cohen YC, Scott E, Carson RL, Heuck C, Gan R, Ackerman B, Zhang J, Caplan E, Parekh T, Mateos MV. Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis. Ann Hematol, 2025. e-Pub 2025. PMID: 41335212.
- Lee HC, Zonder JA, Dhodapkar MV, Jagannath S, Hoffman JE, Suvannasankha A, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martinez-Lopez J, DeVeaux M, Roccia T, Chokshi D, Seraphin M, Knorr K, Boyapati A, Hazra A, Rodriguez Lorenc K, Kroog GS, Bumma N, Richter J. Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Clin Lymphoma Myeloma Leuk, 2025. e-Pub 2025. PMID: 41387038.
- van de Donk NWCJ, Chari A, Martin T, Krishnan A, Rasche L, Ye JC, Popat R, Lipe B, Rodriguez C, Schinke C, Skerget S, Vishwamitra D, Verona R, Gong J, Singh I, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Smit MD, Heuck C, Mateos MV. Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma. Cancer Med 14(19):e71276, 2025. e-Pub 2025. PMID: 41036677.
- Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai Y, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplant Cell Ther, 2025. e-Pub 2025. PMID: 40752590.
- Chari, A, Touzeau, C, Schinke, C, Minnema, MC, Berdeja, JG, Oriol, A, Van De Donk, NW, Rodríguez-Otero, P, Morillo, D, Martinez-Chamorro, C, Mateos, MV, Costa, LM, Caers, J, Rasche, L, Krishnan, A, Ye, JC, Karlin, L, Lipe, B, Vishwamitra, D, Skerget, S, Verona, R, Ma, X, Qin, X, Ludlage, H, Campagna, M, Masterson, T, Hilder, BW, Tolbert, J, Renaud, T, Goldberg, JD, Kane, C, Heuck, C, San Miguel, JF, Moreau, P. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1). The Lancet Haematology 12(4):e269-e281, 2025. e-Pub 2025. PMID: 40090350.
- Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
- Horwitz SM, Feldman TA, Ye JC, Khodadoust MS, Munoz J, Hamlin PA, Kim YH, Wilcox RA, Patel MR, Coffey G, Innes A, Betz A, Holland J, Guzman CB, Smith SM. Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. Leuk Lymphoma:1-11, 2025. e-Pub 2025. PMID: 39921522.
- Ye JC, Biran N, Nair S, Lin X, Qi K, Londhe A, Ammann E, Renaud T, Kane C, Parekh T, Gray K, Peterson S, Costa LJ. Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 25(2):124-134.e5, 2025. e-Pub 2025. PMID: 39271448.
- Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Kebriaei, P, Aljawai, YM, Khan, HN, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38760362.
- Manzar GS, Dudzinski SO, Yoder AK, Seo A, Nasr LF, Rafei H, Becnel MR, Patel KK, Lee HC, Kaufman GP, Gaballa MM, Ye JC, Saini N, Thomas SK, Amini B, Orlowski RZ, Dabaja BS, Pinnix CC, Gunther JR, Wu SY, Fang PQ. Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy. Clin Lymphoma Myeloma Leuk, 2024. e-Pub 2024. PMID: 39709251.
- Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, Lipe B, Qin X, Campagna M, Masterson T, Tomlinson C, Hilder B, Tolbert J, Renaud T, Smit MD, Gray K, Kane C, Heuck C, van de Donk NWCJ. Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab. Clin Lymphoma Myeloma Leuk 24(10):665-693.e14, 2024. e-Pub 2024. PMID: 38871558.
- Bumma, N, Richter, J, Jagannath, S, Lee, HC, Hoffman, JE, Suvannasankha, A, Zonder, J, Shah, M, Lentzsch, S, Baz, R, Maly, J, Namburi, S, Pianko, M, Ye, JC, Wu, KL, Silbermann, R, Min, CK, Vekemans, MC, Munder, M, Byun, JM, Martinez-Lopez, J, Cassady, K, DeVeaux, M, Chokshi, D, Boyapati, A, Hazra, A, Yancopoulos, G, Sirulnik, LA, Rodriguez-Lorenc, K, Kroog, G, Houvras, Y, Dhodapkar, M. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology 42(22):2702-2712, 2024. e-Pub 2024. PMID: 38879802.
- Rodríguez-Otero, P, Usmani, S, Cohen, AD, Van De Donk, NW, Leleu, X, Pérez-Larraya, JG, Manier, S, Nooka, AK, Mateos, MV, Einsele, H, Minnema, MC, Cavo, M, Derman, B, Puig, N, Gay, F, Ho, J, Chng, WJ, Kastritis, E, Gahrton, G, Weisel, K, Nagarajan, C, Schjesvold, F, Mikhael, J, Costa, LM, Raje, N, Zamagni, E, Hajek, R, Weinhold, N, Yong, K, Ye, JC, Sidhana, S, Merlini, G, Martin, T, Lin, Y, Chari, A, Popat, R, Kaufman, JL. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. The lancet oncology 25(5):e205-e216, 2024. e-Pub 2024. PMID: 38697166.
- Stino, AM, Bumma, N, Smith, R, Davalos, L, Allen, J, Ye, JC, Pianko, M, Campagnaro, E, Fierro, C, Awad, A, Murdock, B, Pietrzak, M, Loszanski, G, Kline, DM, Efebera, Y, Elsheikh, B. Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy. European Journal of Neurology 31(3), 2024. e-Pub 2024. PMID: 38015467.
- Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, Fu AZ, Lafeuille MH, Thompson-Leduc P, Khare V, Reitan J, Milkovich G, Kaila S, Davies F, Usmani SZ. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clin Lymphoma Myeloma Leuk 24(1):55-63, 2024. e-Pub 2024. PMID: 37838502.
- Tang G, Wu Y, Lin P, Toruner GA, Hu S, Li S, Qazilbash MH, Orlowski RZ, Ye C, Xu J, Nahmod KA, Medeiros LJ, Tang Z. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. Cancers (Basel) 15(23), 2023. e-Pub 2023. PMID: 38067393.
- Janakiram M, Ye JC. Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice. ASCO Daily News, 2023. e-Pub 2023.
- Vo, JN, Wu, YM, Mishler, J, Hall, S, Mannan, R, Wang, L, Ning, Y, Zhou, J, Hopkins, AC, Estill, JC, Chan, WK, Yesil, J, Cao, X, Rao, A, Tsodikov, A, Talpaz, M, Cole, C, Ye, JC, Ailawadhi, S, Berdeja, JG, Hofmeister, CC, Jagannath, S, Jakubowiak, AJ, Krishnan, A, Kumar, SK, Levy, MY, Lonial, S, Orloff, GJ, Siegel, DS, Trudel, S, Usmani, S, Vij, R, Wolf, J, Zonder, JA, Bergsagel, PL, Auclair, D, Cho, HJ, Robinson, DR, Chinnaiyan, AM. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nature communications 13(1), 2022. e-Pub 2022. PMID: 35768438.
- Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines(R) Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw 20(6):622-634, 2022. e-Pub 2022. PMID: 35714675.
- Vo JN, Wu YM, Mishler J, Hall S, Vats P, Mannan R, Wang L, Ning Y, Zhou J, Hopkins AC, Estill J, Chan WKB, Yesil J, Cao X, Rao A, Tsodikov A, Talpaz M, Cole CE, Ye JC, Bergsagel L, Auclair D, Robinson DR, Chinnaivan AM. The Genetic Heterogeneity and Drug Resistance Mechanisms of Relapsed Refractory Multiple Myeloma. Nat Commun 13(1):3750, 2022. e-Pub 2022.
- Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan S. The role of biomarkers in personalized immunotherapy. Biomark Res 10(1):32, 2022. e-Pub 2022.
- Ye JC, Horne S, Zhang JZ, Jackson L, Heng HH. Therapy Induced Genome Chaos: A Novel Mechanism of Rapid Cancer Drug Resistance. Front Cell Dev Biol, 2021. e-Pub 2021.
- Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies 14(1):66, 2021. e-Pub 2021.
- Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond 14(1):115, 2021. e-Pub 2021.
- Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell R, Holstein S, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jkubowiak A, Morgan GJ, a K, Jacson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, San Miguel J, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International Harmonization in Performing and Reporting Minimal Residual Disease Assessment in Multiple Myeloma Trials. Leukemia, 2020. e-Pub 2020.
- Ye JC, Chen J, Liu G, Heng HH. Somatic Genomic Mosaicism in Multiple Myeloma. Front Genet 11:388, 2020. e-Pub 2020.
- Ye JC, Sharpe Z, Heng HH. Origins and Consequences of Chromosomal Instability: From Cellular Adaptation to Genome Chaos-Mediated System Survival. Genes 11(10):1162, 2020. e-Pub 2020.
- Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, Campagnaro E, Nachar VR. Optimal Sequence Of Daratumumab And Elotuzumab In Relapsed And Refractory Multiple Myeloma. Leuk Lymphoma 61(3):691-698, 2020. e-Pub 2020.
- Ye JC, Chen L, Chen J, Parkin B, Polk A, Kandarpa M, Cole CE, Campagnaro EL, Robinson D, Wu YM, Talpaz M, Yesil J, Auclair D, Bergsagel PL, Chinnaiyan A, Baladandayuthapani V. Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients. Blood 134:4360, 2019. e-Pub 2019.
- Ye JC, Sharpe Z, Alemara S, Mackenzie S, Liu G, Abdallah B, Horne S, Regan S, Heng HH. Micronuclei and Genome Chaos: Changing the System Inheritance. Genes 10(5):366, 2019. e-Pub 2019.
- Skala SL, Ye JC, Stumph J, Macon WR, Quinones FR, Khachaturov V, Ketterling RP, Dewar R. Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma. Clin Pathol, 2019. e-Pub 2019.
- Modi D, Ye JC, Surapaneni M, Singh V, Chen W, Jang H, Deol A, Ayash L, Alavi A, Ratanatharathorn V, Uberti JP. Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients. Am J Hematol 94(10):1072-1080, 2019. e-Pub 2019.
- Ye JC, Stilgenbauer L, Moy A, Liu G, Heng HH. What Is Karyotype Coding and Why Is Genomic Topology Important for Cancer and Evolution?. Front Genet 10:1082, 2019. e-Pub 2019.
- Liu G, Ye CJ, Chowdhury SK, Abdallah BY, Horne SD, Nichols D, Heng HH. Detecting Chromosome Condensation Defects in Gulf War Illness Patients. Curr Genomics 19(3):200-206, 2018. e-Pub 2018. PMID: 29606907.
- Heng HH, Horne SD, Chaudhry S, Regan SM, Liu G, Abdallah BY, Ye CJ. A Postgenomic Perspective on Molecular Cytogenetics. Curr Genomics 19(3):227-239, 2018. e-Pub 2018.
- Ye JC, Regan S, Liu G, Alemara S, Heng HH. Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems. Mol Cytogenet 11:31, 2018. e-Pub 2018.
- Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 77:65, 2018. e-Pub 2018.
- Heng HH, Regan SM, Liu G, Ye CJ. Why It Is Crucial to Analyze Non Clonal Chromosome Aberrations Or NCCAs?. Mol Cytogenet 9:15, 2016. e-Pub 2016.
- Abdallah BY, Horne SD, Kurkinen M, Stevens JB, Liu G, Ye CJ, Barbat J, Bremer SW, Heng HH. Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer. Syst Biol Reprod Med 60(1):2-13, 2014. e-Pub 2014.
- Stevens JB, Liu G, Abdallah BY, Horne SD, Ye KJ, Bremer SW, Ye CJ, Krawetz SA, Heng HH. Unstable genomes elevate transcriptome dynamics. Int. J. Cancer 134(9):2074-2087, 2014. e-Pub 2014.
- Liu G, Stevens JB, Horne SD, Abdallah BY, Ye KJ, Bremer SW, Ye CJ, Chen DJ, Heng HH. Genome chaos: Survival strategy during crisis. Cell Cycle 13(4):528-537, 2014. e-Pub 2014.
- Heng HH, Bremer SW, Stevens JB, Horne SD, Liu G, Abdallah BY, Ye KJ, Ye CJ. Chromosomal instability (CIN): What it is and why it is crucial to cancer evolution. Cancer Metastasis Rev 32(3-4):325-340, 2013. e-Pub 2013.
- Horne SD, Stevens JB, Abdallah BY, Liu G, Bremer SW, Ye CJ, Heng HH. Why imatinib remains an exception of cancer research. J. Cell. Physiol 228(4):665-670, 2013. e-Pub 2013.
- Stevens JB, Abdallah BY, Liu G, Horne SD, Bremer SW, Ye KJ, Huang JY, Kurkinen M, Ye CJ, Heng HH. Heterogeneity of cell death. Cytogenet. Genome Res 139(3):164-173, 2013. e-Pub 2013.
- Stevens JB, Horne SD, Abdallah BY, Ye CJ, Heng HH. Chromosomal instability and transcriptome dynamics in cancer. Cancer Metastasis Rev 32(3-4):391-402, 2013. e-Pub 2013.
- Heng HH, Liu G, Stevens JB, Abdallah BY, Horne SD, Ye KJ, Bremer SW, Chowdhury SK, Ye CJ. Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenet Genome Res 139(3):144-57, 2013. e-Pub 2013.
- Chandrakasan S, Ye CJ, Chitlur M, Mohamed AN, Rabah R, Konski A, Heng HH, Savaşan S. Malignant fibrous histiocytoma two years after autologous stem cell transplant for Hodgkin lymphoma: evidence for genomic instability. Pediatr Blood Cancer 56(7):1143-5, 2011. e-Pub 2011.
- Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, Hüttemann M, Tainsky MA, Wu GS, Xie Y, Zhang K, Heng HH. Diverse system stresses: Common mechanisms of chromosome fragmentation. Cell Death Dis 2(6):89, 2011. e-Pub 2011.
- Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Abdallah BY, Horne SD, Ye CJ. Decoding the genome beyond sequencing: The new phase of genomic research. Genomics 98(4):242-252, 2011. e-Pub 2011.
- Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ. Evolutionary Mechanisms and Diversity in Cancer Adv. Cancer Res 112:217-253, 2011. e-Pub 2011.
- Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Ye CJ. Genetic and epigenetic heterogeneity in cancer: The ultimate challenge for drug therapy. Curr Drug Targets 11(10):1304-1316, 2010. e-Pub 2010.
- Stevens JB, Abdallah BY, Regan SM, Liu G, Bremer SW, Ye CJ, Heng HH. Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation. Mol Cytogenet 3(1):58, 2010. e-Pub 2010.
- Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ. The evolutionary mechanism of cancer. J. Cell. Biochem 109(6):1072-1084, 2010. e-Pub 2010.
- Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective. J. Cell. Physiol 220(3):538-547, 2009. e-Pub 2009.
- Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, Heng HH. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol 219(2):288-300, 2009. e-Pub 2009.
- Heng HH, Stevens JB, Lawrenson L, Liu G, Ye KJ, Bremer SW, Ye CJ. Patterns of genome dynamics and cancer evolution. Cell. Oncol 30(6):513-514, 2008. e-Pub 2008.
- Ye CJ, Liu G, Bremer SW, Heng HH. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res 118(2-4):237-46, 2007. e-Pub 2007.
- Stevens JB, Liu G, Bremer SW, Ye KJ, Xu W, Xu J, Sun Y, Wu GS, Savasan S, Krawetz SA, Ye CJ, Heng HH. Mitotic cell death by chromosome fragmentation. Cancer Res 67(16):7686-7694, 2007. e-Pub 2007.
- Heng HH, Liu G, Bremer S, Ye KJ, Stevens J, Ye CJ. Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 49(3):195-204, 2006. e-Pub 2006.
- Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 208(2):461-72, 2006. e-Pub 2006.
- Heng HH, Bremer SW, Stevens J, Ye KJ, Miller F, Liu G, Ye CJ. Cancer progression by non-clonal chromosome aberrations. J. Cell. Biochem 98(6):1424-1435, 2006. e-Pub 2006.
- Ye CJ, Stevens JB, Liu G, Ye KJ, Yang F, Bremer SW, Heng HH. Combined multicolor-FISH and immunostaining. Cytogenet Genome Res 114(3-4):227-34, 2006. e-Pub 2006.
- Heng HH, Stevens JB, Liu G, Bremer SW, Ye CJ. Imaging genome abnormalities in cancer research. Cell Chromosome 3(1):1, 2004. e-Pub 2004. PMID: 14720303.
- Heng HH, Goetze S, Ye CJ, Liu G, Stevens JB, Bremer SW, Wykes SM, Bode J, Krawetz SA. Chromatin loops are selectively anchored using scaffold/matrix-attachment regions. J. Cell. Sci 117(7):999-1008, 2004. e-Pub 2004.
- Takeuchi T, Heng HH, Ye CJ, Liang SB, Iwata J, Sonobe H, Ohtsuki Y. Down-regulation of a novel actin- binding molecule, skeletrophin, in malignant melanoma. Am J Pathol 163(4):1395-404, 2003. e-Pub 2003. PMID: 14507647.
- Heng HH, Ye CJ, Yang F, Ebrahim S, Liu G, Bremer SW, Thomas CM, Ye J, Chen TJ, Tuck-Muller C, Yu JW, Krawetz SA, Johnson A. Analysis of marker or complex chromosomal rearrangements present in pre- and post-natal karyotypes utilizing a combination of G-banding, spectral karyotyping and fluorescence in situ hybridization. Clin Genet 63(5):358-67, 2003. e-Pub 2003.
- Ye CJ, Lu W, Liu G, Bremer SW, Wang YA, Moens P, Hughes M, Krawetz SA, Heng HH. The combination of SKY and specific loci detection with FISH or immunostaining. Cytogenet Cell Genet 93(3-4):195-202, 2001. e-Pub 2001.
- Schmid C, Heng HH, Rubin C, Ye CJ, Krawetz SA. Sperm nuclear matrix association of the PRM1-- >PRM2-->TNP2 domain is independent of Alu methylation. Mol Hum Reprod 7(10):903-11, 2001. e-Pub 2001.
- Heng HH, Liu G, Lu W, Bremer S, Ye CJ, Hughes M, Moens P. Spectral karyotyping (SKY) of mouse meiotic chromosomes. Genome 44(2):293-8, 2001. e-Pub 2001.
- Heng HH, Krawetz SA, Lu W, Bremer S, Liu G, Ye CJ. Re-defining the chromatin loop domain Cytogenet. Cell Genet 93(3-4):155-161, 2001. e-Pub 2001.
- Tarsounas M, Heng HH, Ye JC, Pearlman RE, Moens PB. Identification of the mouse beta'-COP Golgi component as a spermatocyte autoantigen in scleroderma and mapping of its gene Copb2 to mouse chromosome 9. Cytogenet Cell Genet 87(3-4):201-4, 1999. e-Pub 1999.
- Omori F, Messner HA, Ye JC, Gronda MV, O'Neill JP, Atkins H, Heng HH. Nontargeted stable integration of recombinant adeno-associated virus into human leukemia and lymphoma cell lines as evaluated by fluorescence in situ hybridization. Hum Gene Ther 10(4):537-43, 1999. e-Pub 1999.
- Ye J, Cao Q, Su X, Huang Q, Ma Z, Wang Z, Huang W, Chen Z, Chen S. Biological and clinical significance of cytogenic study on 100 acute lymphoblastic leukemia and 219 acute non-lymphoblastic leukemia. Chin Med J (Engl) 110(2):90-5, 1997. e-Pub 1997.
- Mao M, Yu M, Tong JH, Ye J, Zhu J, Huang QH, Fu G, Yu L, Zhao SY, Waxman S, Lanotte M, Wang ZY, Tan JZ, Chan SJ, Chen Z. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocyctic leukemia cell. Proc Natl Acad Sci U S A:5910-4, 1996. e-Pub 1996. PMID: 8650192.
- Chen SJ, Cao Q, Ma ZG, Su XY, Xong SM, Ye J, Wang ZY, Li XS, Shen ZX, Zhang FQ, Sun GL, Fang ZW, Ouyang RR, Zhu XH, Ying DM, Gu LJ, Chen Z. Cytogenic analysis and its prognostic significance in acute non-lymphoblastic leukemia. Chinese Journal of Hematology, 1996. e-Pub 1996.
Review Articles
- Kumar S, Richter J, Usmani SZ, Cohen YC, Ye JC, Mateos MV, Hungria V, Zamagni E. Extramedullary Disease-Achilles Heel in Myeloma?. Am J Hematol, 2025. e-Pub 2025. PMID: 41462032.
- Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia 39(3):543-554, 2025. e-Pub 2025. PMID: 39870767.
- Sankar, K, Ye, JC, Li, Z, Zheng, L, Song, W, Hu-Lieskovan, S. The role of biomarkers in personalized immunotherapy. Biomarker Research 10(1), 2022. e-Pub 2022. PMID: 35585623.
Editorials
- Ye, JC, Heng, H. Preface. Methods in Molecular Biology 2825:v-vi, 2024.
Book Chapters
- Ye, JC, Heng, H. The New Era of Cancer Cytogenetics and Cytogenomics, 3-37, 2024.
- Ye, JC, Heng, H. Tracking Karyotype Changes in Treatment-Induced Drug-Resistant Evolution, 263-280, 2024.
- Ye, JC, Tang, G. Optical Genome Mapping, 113-124, 2024.
- Chen J, Ye JC. Chronic Lymphocytic Leukemia. In: Oncology Board Review, 2022.
- Ye, JC, Regan, S, Liu, G, Abdallah, B, Horne, S, Heng, HH. Unclassified Chromosome Abnormalities and Genome Behavior in Interphase. In: Human Interphase Chromosomes, 2020.
- Heng, HH, Liu, G, Alemara, S, Regan, S, Armstrong, Z, Ye, JC. The Mechanisms of How Genomic Heterogeneity Impacts Bio-Emergent Properties: The Challenges for Precision Medicine. In: Embracing Complexity in Health, 2019.
- Heng HH, Liu G, Ye JC. Experimental Induction of Genome Chaos. In: Methods Mol Biol, 337-352, 2018.
- Ye JC, Heng HH. High Resolution Fiber-Fluorescence In Situ Hybridization. In: Methods Mol Biol Protocols and Applications, 151-166, 2017.
- Ye JC, Liu G, Heng HH. Simultaneous Fluorescence Immunostaining and FISH. In: Fluorescence In Situ Hybridization (FISH), 301-325, 2016.
- Ye JC, Lawrenson L, Liu G, Stevens JB, Ye KJ, Bremer SW, and Heng HH. Simultaneous fluorescence immunostaining and FISH. In: Fluorescence in situ hybridization (FISH) Application, 193-216, 2009.
Books (edited and written)
- Heng, HH, Ye, JC. Cancer Cytogenetics and Cytogenomics (Methods in Molecular Biology Series), 2023.
Letters to the Editor
- Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK. Long-term outcomes and treatment patterns in Waldenstrom macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. Blood Cancer J 15: 211, 2025.
- Zou YS, Klausner M, Ghabrial J, Stinnett V, Long P, Morsberger L, Murry JB, Beierl K, Gocke CD, Xian RR, Toomer KH, Ye JC, Orlowski RZ, Huff CA, Ali SA, Imus PH, Gocke CB, Tang G. A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping. Blood Cancer J 14: 78, 2024.
Patient Reviews
CV information above last modified February 25, 2026